CLINICAL STUDY PROTOCOL - Moderna
history of SARS-CoV-2 infection but whose locations or circumstances put them at appreciable risk of acquiring COVID-19 and/or SARS-CoV-2 infection. Figure 1 shows the study flow. Participants will be randomly assigned to receive injections of either 100 µg of mRNA-1273 vaccine or a placebo control in a 1:1 randomization ratio.
Download CLINICAL STUDY PROTOCOL - Moderna
Information
Domain:
Source:
Link to this page:
Documents from same domain
Vaccination Provider Fact Sheet | EUA | Moderna COVID-19 ...
www.modernatx.comPrimary Series: Each primary series dose of the Moderna COVID-19 Vaccine is 0.5 mL. The Moderna COVID-19 Vaccine is administered as a primary series of two doses (0.5 mL each) ... See this Fact Sheet for instructions for preparation and administration. This Fact Sheet may have . Revised: Dec/9/2021 2
COVID-19 Vaccine (mRNA-1273) - Moderna
www.modernatx.comNov 16, 2020 · Pediatric respiratory syncytial virus (RSV) vaccine Future respiratory combo Worldwide mRNA-1189 Epstein-Barr virus (EBV) vaccine Worldwide mRNA-1851 Influenza H7N9vaccine ... Presentation of older adults Phase 1 data October 22, 2020 Phase 3 COVE study completed enrollment of 30,000 participants Sept 29, 2020 Publication of older adults …
Storage Handling - Moderna
www.modernatx.comStorage and Handling The information in this Fact Sheet supersedes the information on the vial and carton labels. During storage, minimize exposure to room light. The Moderna COVID-19 Vaccine multiple-dose vials are stored frozen between -50º to -15ºC (-58º to 5ºF). Store in the original carton to protect from light.
WHITE PAPER mRNA Vaccines - Moderna
www.modernatx.comsyringe Investment decisions in production facility (3-5yr lead time) Standardized (mg scale) Standardized (kg scale) Standardized multiproduct facility (kg scale) mRNA vaccine DNA vaccine: Bespoke facility ($100mm-$1bn) (tonne scale) Specialized delivery system Standard needle &
US00000010898574B220210126
www.modernatx.comTitle: US00000010898574B220210126 Subject: 00780001 Created Date: 20210106010406Z
IMPORTANT PRESCRIBING INFORMATION Booster Dose …
www.modernatx.comreport vaccine administration errors to the Vaccine Adverse Event Reporting System (VAERS). See the Fact Sheet for Vaccination Providers for reporting instructions. Additional Resources To access the most recent Moderna COVID-19 Vaccine Fact Sheets, please scan the QR code or
Vaccine Recipient Fact Sheet | EUA | Moderna COVID-19 …
www.modernatx.comEMERGENCY USE AUTHORIZATION (EUA) OF THE MODERNA COVID-19 VACCINE TO PREVENT CORONAVIRUS DISEASE 2019 (COVID-19) IN INDIVIDUALS 18 YEARS OF AGE AND OLDER You are being offered the Moderna COVID-19 Vaccine to prevent Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV-2. This Fact Sheet contains information to …
Reimbursement for the Moderna COVID-19 Vaccine
www.modernatx.comcharge for administration. However, vaccination providers may seek appropriate reimbursement from a program or plan that covers COVID-19 vaccine administration fees for the vaccine recipient (private insurance, Medicare, Medicaid, HRSA COVID-19 Uninsured Program for non-insured recipients).
Moderna COVID-19 Vaccine EUA Letter of Authorization
www.modernatx.comJan 31, 2022 · vaccine in individuals 18 years of age or older who have undergone solid organ transplantation, or individuals 18 years of age or older who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise, FDA reviewed safety and effectiveness data reported in two manuscripts on solid organ transplant recipients.
Hoja informativa para receptores de la vacuna | EUA ...
www.modernatx.comLa vacuna contra la COVID-19 de Moderna es una vacuna no aprobada. En ensayos clínicos, aproximadamente 15,400 personas de 18 años en adelante han recibido al menos 1 dosis de la vacuna contra la COVID-19 de Moderna. Millones de personas han recibido la vacuna en virtud
Related documents
Infection Prevention and Control Assessment Tool for ...
www.cdc.govInfection Prevention and Control Assessment Tool for Hemodialysis Facilities This tool is intended to assist in the assessment of infection control programs and practices in dialysis facilities. In order to complete the assessment, direct observation of infection control practices will be necessary. To facilitate the
Clinical management of severe acute respiratory infection ...
www.who.intClinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected Interim guidance 13 March 2020 This is the second edition (version 1.2) of this document, which was originally adapted from Clinical management of severe acute respiratory infection when MERS-CoV infection is suspected (WHO, 2019).
Surgical Site Infection Prevention - Hopkins Medicine
www.hopkinsmedicine.org– Standardized definitions for infection and risk-stratification methodology – National data on pooled mean and percentiles – We use NHSN to perform SSI surveillance for surgical procedures including craniotomy, laminectomy, spinal fusion, C-section, and CABG
Nipah Virus (NiV) - Centers for Disease Control and …
www.cdc.govInfection with Nipah virus is associated with encephalitis (inflammation of the brain). After exposure and an incubation period of 5 to 14 days,illness presents with 3-14 days of fever and headache, followed by drowsiness, disorientation and mental confusion. These signs and symptoms can progress to coma within 24-48 hours.
The infection fatality rate of COVID-19 inferred from ...
biomechanics.stanford.eduThe infection fatality rate (IFR), the probability of dying for a person who is infected, is ... CFR is the ratio of COVID-19 deaths divided by the number of documented cases, i.e. patients with symptoms who were tested and found to be PCR-positive for the virus. The WHO envoy who visited China also conveyed the message that there
Comparison of outcomes from COVID infection in pediatric ...
www.medrxiv.orgDec 30, 2021 · CoV-2 infection. Based on CDC data, Delta was the predominant variant at that time (98.6-99.1%)1; (c) the Delta-2 cohort (n = 77,692) – patients who had their first SARS-CoV-2 infections between 11/16/2021–11/30/2021, immediately before the Omicron variant was detected in the US, and had no prior SARS-CoV-2 infection.
Protection afforded by prior infection against SARS-CoV-2 ...
www.medrxiv.orgJan 05, 2022 · exact matched in a ratio of one-to-five by sex, 10-year age group, nationality, and calendar week of the PCR test (Figure 1 and Table 1). Infection with Alpha, Beta, or Delta variants was ascertained using real-time reverse-transcription PCR (RT-qPCR) genotyping of the positive clinical samples 11,12(Section S1).